menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

New Developments in Incretins and SGLT Inhibitors

New Developments in Incretins and SGLT Inhibitors
RestartResume
The physiological effects of glucagon-like peptide-1 (GLP-1) are exciting because of the potential clinical relevance in treating two of the major ...
  • Overview

    The physiological effects of glucagon-like peptide-1 (GLP-1) are exciting because of the potential clinical relevance in treating two of the major abnormalities that contribute to type 2 diabetes: impaired insulin secretion and excessive glucagon secretion. GLP-1 also appears to have effects on gastric emptying and appetite suppression. Join host Dr. Steven Edelman and his guest Dr. Robert Henry, professor of medicine at the University of California, San Diego, and chief of both the section of endocrinology, metabolism and diabetes and the Center for Metabolic Research at the VA Medical Center in San Diego.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.